



## PRESS RELEASE

# Ongoing enrollment in the first-in-man trial of CARMAT's bioprosthetic heart

**Paris, September 8, 2014**

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, providing a therapeutic alternative for people suffering from end-stage heart failure, today confirms that it has completed half of the feasibility study on its bioprosthetic heart and announces an ongoing enrollment for two more patients.

The study encompasses enrollment of four patients who are in an immediate life-threatening situation due to irreversible biventricular heart failure.

The criteria for success notably include the patient's 30-day survival following the implant and the functional recovery of their vital organs. On this basis, the two independent committees overseeing the study met on Thursday and Friday. A favorable opinion regarding the enrollment of additional patients was delivered.

*"We would like to wholeheartedly thank our investigation centers' clinical teams for their involvement alongside us, and today especially the experienced teams at the Nantes University Hospital.",* said Marcello Conviti, Chief Executive Officer of CARMAT. *"This milestone has been made possible by their trust, as well as that of our staff, partners and shareholders."*

The Company would like to remind readers that, in accordance with good clinical practice and subject to regulatory obligations or specific circumstances, it is not planning to publish any information on the interim results of this ongoing feasibility study.

### **About CARMAT: the world's most advanced total artificial heart project**

**The only credible response for all cases of end-stage heart failure, which is a real public health issue:** CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 20 million patients in Europe and the United States. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

**The result of combining two types of unique expertise:** the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

**Imitating the natural heart:** given its size, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

**A project leader acknowledged at a European level:** with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

**Strongly committed, prestigious founders and shareholders:** [Truffle Capital](#), a leading European venture capital firm, [Airbus Group](#), Professor [Alain Carpentier](#), the [Centre Chirurgical Marie Lannelongue](#) and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

**For more information:** [www.carmatsa.com](http://www.carmatsa.com)



**Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company's objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the *Document de Référence* filed with the *Autorité des Marchés Financiers* under number D.14-045 on March 17, 2014 and the *Note d'Opération* that was approved with visa no. 11-308 on July 11, 2011, changes in economic conditions, the financial markets or the markets in which Carmat operates. In particular, no guarantee can be given concerning the Company's ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark



**CARMAT**

**Marcello Conviti**  
CEO

**Patrick Coulombier**  
COO

**Valérie Leroy**  
Director of Marketing  
& Investor Relations  
Tel.: +33 (0)1 39 45 64 50  
[contact@carmatsas.com](mailto:contact@carmatsas.com)

**Alize RP**

Press Relations

**Caroline Carmagnol**  
Tel.: +33 (0)1 70 22 53 90  
[caroline@alizerp.com](mailto:caroline@alizerp.com)



**NewCap**

Financial Communication  
and Investor Relations

**Dusan Oresansky**  
**Emmanuel Huynh**  
Tel.: +33 (0)1 44 71 94 94  
[carmat@newcap.fr](mailto:carmat@newcap.fr)

Name: **CARMAT**  
ISIN code: **FR0010907956**  
Ticker: **ALCAR**